This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aralez Pharmaceuticals Inc.
Drug Names(s): MK-5348, SCH 530348, Thrombin Receptor Antagonist (TRA)
Description: SCH 530348 binds selectively to a thrombin receptor on platelets, called Protease Activated Receptor-1 (PAR-1), and is therefore a member of a potentially new class of drugs called thrombin receptor antagonists (TRA).
Deal Structure: SCH 530348 was originally developed by Schering-Plough.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was closed in November 2009.
Merck and Aralez
In September 2016, Aralez Pharmaceuticals announced that it acquired the U.S. and Canadian rights to ZONTIVITY (vorapaxar), pursuant to an asset purchase agreement entered into between Merck and Aralez Pharmaceuticals Trading, a subsidiary of Aralez, based in Ireland.
The asset purchase agreement included an initial upfront payment of $25 million, which was paid from cash on hand....See full deal structure in Biomedtracker
Partners: Merck & Co., Inc.
Pink Sheet Zontivity Reviewers
Additional information available to subscribers only: